JAK inhibitors in crohn’s disease: ready to go?

References

• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017 Apr 29;389(10080):1741–1755. Epub 2016 Dec 1. PMID: 27914655.
   PubMed Web of Science ®Google Scholar
• Roda G, Ng SC, Kotze PG, et al. Publisher Correction: crohn’s disease. Nat Rev Dis Primers. 2020 Apr 6;6(1):26. Erratum for: Nat Rev Dis Primers. 2020 Apr 2;6(1):22. PMID: 32251284.
   PubMedGoogle Scholar
• Pazmandi J, Kalinichenko A, Ardy RC, et al. Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol Rev. 2019 Jan;287(1):162–185. PMID: 30565237; PMCID: PMC7379380.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, EV L Jr, Colombel JF, et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan;17(1):471–478. Epub 2010 Aug 19. PMID: 20725943.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Fernandes C, et al. Catching the therapeutic window of opportunity in early crohn’s disease. Curr Drug Targets. 2014;15(11):1056–1063. PMID: 25198784.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis, A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterol. 2021Apr;160(5):1570–1583. Epub 2021 Feb 19. PMID: 33359090
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in crohn’s disease: medical treatment. J Crohns Colitis. 2020 Jan 1;14(1):4–22. PMID: 31711158.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015Apr;417:613–623. Epub 2015 Feb 4. PMID: 25652884
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016 Jan 7;7(1):e135. PMID: 26741065; PMCID: PMC4737871.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019 May;4(5):341–353. Epub 2019 Feb 27. PMID: 30824404.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 Jul;13(7):693–703. Epub 2017 Feb 17. PMID: 28164724.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019 May16;12:1756284819848631. PMID: 31205486; PMCID: PMC6535722.
   Web of Science ®Google Scholar
• Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019 Oct;68(10):1893–1899. Epub 2019 Jun 21. PMID: 31227590.
   PubMed Web of Science ®Google Scholar
• Gibson SA, Yang W, Yan Z, et al. CK2 Controls Th17 and regulatory t cell differentiation through inhibition of foxO1. J Immunol. 2018 Jul 15;201(2):383–392. Epub 2018 Jun 11. PMID: 29891553; PMCID: PMC6040220.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Furfaro F, et al. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018 Jul;27(7):595–599. Epub 2018 Jul 6. PMID: 29938545.
   PubMed Web of Science ®Google Scholar
• Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i4–i16. PMID: 30806710; PMCID: PMC6657570.
   PubMedGoogle Scholar
• Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155–62. Epub 2015 Nov 25. PMID: 26608188; PMCID: PMC4971816.
   PubMed Web of Science ®Google Scholar
• Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013 Oct;76: 1–8 Epub 2013 Jul 2. PMID: 23827161
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017 Apr;77(5):521–546. Erratum in: Drugs. 2017 Jun 12; PMID: 28255960; PMCID: PMC7102286.
   PubMed Web of Science ®Google Scholar
• Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067–1077. Epub 2014 May 12. PMID: 24818516.
   PubMed Web of Science ®Google Scholar
• Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013 Oct;27(5):431–438. PMID: 23743669; PMCID: PMC3778139.
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors And S1pr agonists. Front Pharmacol. 2019 Mar13;10:212. PMID: 30930775; PMCID: PMC6425155.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Pj SC. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–1736. PMID: 28467869.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485–93.e2. Epub 2014 Jan 27. PMID: 24480677.
   PubMed Web of Science ®Google Scholar
• Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017Jun;666:1049–1059. Epub 2017 Feb 16. PMID: 28209624; PMCID: PMC5532457
   PubMed Web of Science ®Google Scholar
• Fenster M, Alayo QA, Khatiwada A, et al. Real-World effectiveness and safety of tofacitinib in crohn’s disease and IBD-U: a multicenter study from the TROPIC consortium. Clin Gastroenterol Hepatol. 2021Oct;1910:2207–2209.e3. Epub 2020 Oct 14. PMID: 33068786; PMCID: PMC8044250
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 Jan 21;389(10066):266–275. Epub 2016 Dec 15. PMID: 27988142.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keam SJ. Filgotinib: first approval. Drugs. 2020 Dec;80(18):1987–1997. Erratum in: Drugs. 2021 Feb;81(2):297. PMID: 33237566; PMCID: PMC7858213.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) (Divergence1). [cited 2021 Dec 20]. Available at: https://clinicaltrials.gov/ct2/show/NCT03046056?term=Divergence+1&draw=2&rank=1.
   Google Scholar
• ClinicalTrials.gov. Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease (Divergence2) [cited 2021 Dec 20]. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03077412?term=Divergence+2&draw=2&rank=1.
   Google Scholar
• Mohamed MF, Camp HS, Jiang P, et al. Pharmacokinetics, Safety and Tolerability of ABT-494, a novel selective JAK 1 Inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016 Dec;55(12):1547–1558. PMID: 27272171.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, EV L Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn’s disease. Gastroenterology. 2020Jun;1588:2123–2138.e8. Epub 2020 Feb 8. PMID: 32044319
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Panès JLEEA. Composite endpoint and individual measure of efficacy and safety after 2 years of upadacitinib treatment for crohn’s disease: results from the ongoing phase 2 CELEST open-label extension study. United Eur Gastroenterlogy J. 2020;8:8–142.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Louis E, EV L Jr, et al. Quality of life and work productivity improvements with upadacitinib: phase 2b evidence from patients with moderate to severe crohn’s disease. Adv Ther. 2021May;385:2339–2352. Epub 2021 Mar 23. PMID: 33755884; PMCID: PMC8107073
   PubMed Web of Science ®Google Scholar
• Aguilar D, Revilla L, Garrido-Trigo A, et al. Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the crohn’s disease intestinal mucosa: analysis from the CELEST study. Inflamm Bowel Dis. 2021 Nov 15;27(12):1999–2009. PMID: 34042156; PMCID: PMC8599035.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Nguyen DD, Beattie DT, et al. Development of gut-selective pan-janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. J Crohns Colitis. 2020 Sep 16;14(9):1202–1213. PMID: 32161949; PMCID: PMC7493219.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. TD-1473 for active Ulcerative Colitis (UC) [cited 2021 Dec 20]. Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT02818686.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of TD-1473 in crohn’s disease (DIONE) [cited 2021 Dec 20]. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03635112.
   Google Scholar
• Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients wi. J Clin Pharmacol. 2018Apr;584:434–447. Epub 2017 Dec 21. PMID: 29266308
   PubMed Web of Science ®Google Scholar
• Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual jak3/tec family kinase inhibitor. ACS Chem Biol. 2019 Jun 21;14(6):1235–1242. Epub 2019 May 22. PMID: 31082193.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study to evaluate the efficacy and safety of oral PF-06651600 and PF-06700841 in subjects with moderate to severe crohn’s disease [cited 2021 Dec 21]. Available at: https://clinicaltrials.gov/ct2/show/NCT03395184.
   Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843–862. Epub 2017 Nov 6. Erratum in: Nat Rev Drug Discov. 2017 Dec 28;17 (1):78. PMID: 29104284.
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234–243. Epub 2017 Mar 2. Erratum in: Nat Rev Rheumatol. 2017 May;13(5):320. PMID: 28250461.
   PubMed Web of Science ®Google Scholar
• Cantini F, Blandizzi C, Niccoli L, et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf. 2020 Jul;19(7):861–872. Epub 2020 Jun 17. PMID: 32552289.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Panés J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068–1076. Epub 2019 Oct 9. PMID: 31599001; PMCID: PMC6899755.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.
   Google Scholar
• ClinicalTrials.gov. Filgotinib in the induction and maintenance of remission in adults with moderately to severely active crohn’s disease (DIVERSITY1) [cited 2021 Dec 21]. Available at: https://clinicaltrials.gov/ct2/show/NCT02914561.
   Google Scholar
• ClinicalTrials.gov. Filgotinib in long-term extension study of adults with crohn’s disease (DIVERSITYLTE) [cited 2021 Dec 21]. Available at: https://clinicaltrials.gov/ct2/show/NCT02914600.
   Google Scholar
• Cohen SB, Van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020 Oct 28;;80(3):304–311. Epub ahead of print. Erratum in: Ann Rheum Dis. 2021 May;80(5):e83. PMID: 33115760; PMCID: PMC7892382.
   PubMed Web of Science ®Google Scholar
• Robinson MF, Damjanov N, Stamenkovic B, et al. Efficacy and safety of pf-06651600 (ritlecitinib), a novel JAK3/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020 Oct;72(10):1621–1631. Epub 2020 Sep 7. PMID: 32419304; PMCID: PMC7589242.
   PubMed Web of Science ®Google Scholar
• Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434–447. Epub 2017 Dec 21. PMID: 29266308.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017 Feb;66(2):199–209. Epub 2016 Nov 17. PMID: 27856614.
   PubMed Web of Science ®Google Scholar
• Li Q, Kang C. Mechanisms of action for small molecules revealed by structural biology in drug discovery. Int J Mol Sci. 2020 Jul 24;21(15):5262. Published PMID: 32722222; PMCID: PMC7432558
   Web of Science ®Google Scholar
• Wright S, Yelland M, Heathcote K, et al. Fear of needles--nature and prevalence in general practice. Aust Fam Physician. 2009 Mar;383:172–176 PMID: 19283260
   PubMed Web of Science ®Google Scholar
• Buisson A, Seigne AL, D’Huart MC, et al. The extra burden of infliximab infusions in inflammatory bowel disease. Inflamm Bowel Dis. 2013Oct;1911:2464–2467. PMID: 23942563
   PubMed Web of Science ®Google Scholar
• Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus on surgery for crohn’s disease. J Crohn’s Colitis. 2018 January;12(1):1–16.
   Google Scholar
• Morrow T, Felcone LH. Defining the difference: what Makes Biologics Unique. Biotechnology Healthcare. 2004 Sep;1(4):24–29. PMID: 23393437; PMCID: PMC3564302.
   PubMedGoogle Scholar
• van der Valk ME, Mangen M-J-J, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014Jan;631:72–79. Epub 2012 Nov 7. PMID: 23135759
   PubMed Web of Science ®Google Scholar
• Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51–60. PMID: 27269903.
   PubMed Web of Science ®Google Scholar
• Aguilar D, Revilla L, Garrido-Trigo A, et al. Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the crohn’s disease intestinal mucosa analysis from the celest study. Inflamm Bowel Dis. 2021 Nov 15;27(12):1999–2009. PMID: 34042156; PMCID: PMC8599035.
   PubMed Web of Science ®Google Scholar
• Glassner K, Oglat A, Duran A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study. J Dig Dis. 2020 May;21(5):264–271. Epub 2020 Jun 11. PMID: 32324969.
   PubMed Web of Science ®Google Scholar
• Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol. 2021 Jul 1;37(4):344–350. PMID: 33731642.
   PubMed Web of Science ®Google Scholar
• Reinglas J, Gonczi L, Kurt Z, et al. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol. 2018 Aug 28;24(32):3567–3582. PMID: 30166855; PMCID: PMC6113721.
   PubMed Web of Science ®Google Scholar
• Ben Ghezala I, Charkaoui M, Michiels C, et al. Small molecule drugs in inflammatory bowel diseases. Pharmaceuticals (Basel). 2021 Jun 30;14(7):637. PMID: 34209234; PMCID: PMC8308576.
   PubMedGoogle Scholar
• Singh JA, Saag KG, SL B Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016Jan;681:1–26. Epub 2015 Nov 6. PMID: 26545940
   PubMed Web of Science ®Google Scholar
• Guillo L, Rabaud C, Choy EH, et al. Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide. Clin Gastroenterol Hepatol. 2020 Oct 17;S1542-3565(20):31440–31443. Epub ahead of print. PMID: 33080353.
   Google Scholar
• A NPK, Dörner T, Dougados M, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021Jan;80(1):71–87. Epub 2020 Nov 6. PMID: 33158881; PMCID: PMC7788060
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Becciolini A, Crotti C, et al. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct24;8:212595. PMID: 31692920; PMCID: PMC6821397.
   PubMedGoogle Scholar
• Rubin DT, Reinisch W, Greuter T, et al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. PMID: 34035832; PMCID: PMC8132089.
   Web of Science ®Google Scholar
• ClinicalTrials.gov Study to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease (MANTA) [cited 2021 Dec 21]. Available at: https://clinicaltrials.gov/ct2/show/NCT03201445.
   Google Scholar
• [cited 2021 Dec 21]. Available from:https://www.globenewswire.com/news-release/2021/03/04/2186756/0/en/GALAPAGOS-REPORTS-PRIMARY-ENDPOINT-FOR-THE-ONGOING-FILGOTINIB-MANTA-AND-MANTA-RAy-SAFETY-STUDIES.html.
   Google Scholar